A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
This study will evaluate safety and tolerability of treatment with atogepant for the prevention of episodic migraine over the course of one year.
Inclusion Criteria:
Exclusion Criteria:
Birmingham, Alabama 35211, United States
Chandler, Arizona 85224, United States
Phoenix, Arizona 85020, United States
Lenexa, Kansas 66214, United States